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Antibiotics are commonly used in the management of respiratory disorders such as cystic
fibrosis (CF), non-CF bronchiectasis, asthma and COPD. In those conditions long-term antibi-
otics can be delivered as nebulised aerosols or administered orally. In CF, nebulised colomycin
or tobramycin improve lung function, reduce number of exacerbations and improve quality of
life (QoL). Oral antibiotics, such as macrolides, have acquired wide use not only as anti-
microbial agents but also due to their anti-inflammatory and pro-kinetic properties. In CF,
macrolides such as azithromycin have been shown to improve the lung function and reduce fre-
quency of infective exacerbations. Similarly macrolides have been shown to have some bene-
fits in COPD including reduction in a number of exacerbations. In asthma, macrolides have
been reported to improve some subjective parameters, bronchial hyperresponsiveness and
airway inflammation; however have no benefits on lung function or overall asthma control.
Macrolides have also been used with beneficial effects in less common disorders such as diffuse
panbronchiolitis or post-transplant bronchiolitis obliterans syndrome. In this review we
describe our current knowledge the use of long-term antibiotics in conditions such as CF,
non-CF bronchiectasis, asthma and COPD together with up-to-date clinical and scientific evi-
dence to support our understanding of the use of antibiotics in those conditions.
ª 2013 Elsevier Ltd. All rights reserved.392 86000x1393; fax: þ44 2392 286667.
mail.com, sureshbabu97@hotmail.com (K. Suresh Babu).
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Respiratory diseases are commonly associated with signifi-
cant morbidity and mortality, affecting patients’ quality of
life (QoL) and leading to associated increased costs to the
health services. Therefore therapeutic anti-bacterial and
anti-inflammatory modalities that may reduce the fre-
quency of exacerbations, the need for hospitalisation and
resulting improvement in patients QOL may have important
health economic implications. In recent years there has
been an improvement in our understanding of managing
respiratory conditions using anti-bacterial and/or anti-
inflammatory agents. Control of infective exacerbations
and thereby the inflammation with oral or aerosol prepa-
rations of antibiotics has been shown to have beneficial
effects in many of respiratory disorders. This review aims to
examine the studies on long-term antibiotic use in man-
agement of respiratory diseases, to identify evidence sup-
porting their role and to discuss their potential clinical
benefits and limitations.
Role for macrolides
Macrolide antibiotics belong to an expansive family of
compounds that are characterized by the presence of a
macrocyclic lactone ring.1 They exert their effects by
binding to 50 s ribosomal RNA and have a broad spectrum of
activity against many organisms.2 The immunomodulatory
properties of macrolides is related to the lactone ring which
is seen with the 14 (erythromycin, clarithromycin and rox-
ithromycin) and the 15 (azithromycin) member macro-
lides.3 Though the precise mechanism of action of
macrolides is unknown it has been proposed that macro-
lides can: attenuate mucous hypersecretion; reduce pro-
duction of pro-inflammatory cytokines which can lead to a
reduction in accumulation and proliferation of neutrophils
in the mucosal epithelium; and a suppressive effect on
lymphocytic activity.4 In human and animal models mac-
rolides suppress the production of cytokines such as inter-
leukin (IL)-5, IL-8, IL-6, IL-1b, IL-10, tumour necrosis factor
(TNF)-a and granulocyte-monocyte colony stimulatingfactor (GM-CSF); inhibit neutrophil adhesion to epithelial
cells; the respiratory burst of neutrophils; and the mucous
secretion from airways.5e9 Macrolides also inhibit RNA-
dependent protein synthesis and binding to the bacterial
ribosomal subunits. Moreover, macrolides attenuate
lipopolysaccharide-induced MUC5AC gene expression and
clarithromycin in particular significantly reduces the
MUC5AC expression at both the mRNA and protein levels.10
It has also been reported that in COPD patients, macrolides
improve macrophage phagocytosis of apoptotic airways
epithelial cells, reduce systemic inflammation and induced
increased expression of macrophage mannose re-
ceptors.11,12 Hence the dual action of enhanced clearance
of apoptotic cells and bacteria may diminish the secondary
necrosis and production of inflammatory mediators.
In patients infected with Pseudomonas (P.) aeruginosa
macrolides have effects on biofilm development. Biofilm
formation and virulence factors in P. aeruginosa are
controlled by a system of bacterial intercommunication,
known as quorum sensing. This system comprises genes
encoding transcriptional activators, namely lasR and rhlR and
macrolides inhibit the transcription of several of these
genes.13,14 Macrolides can affect bacterial adherence of
pathogens like P. aeruginosa15 and consequently there has
beenan increasing interest in theuseofmacrolides inpatients
colonised with pseudomonas. Macrolides have also been pro-
posed to have pro-kinetic activity on the gastrointestinal tract
hence reducing gastro-oesophageal reflux and micro-
aspiration which are common phenomena in pulmonary con-
ditions.16e18 Additionally, macrolides have been reported to
have anti-proliferative actions and slow both bronchial
epithelial cell proliferation and fibroblast migration.19,20
Despite the numerous positive outcomes macrolides
possess, more recently, there have been reports in murine
models21 and CF patients22,23 that long-term macrolides
may be associated with the development of non-
tuberculous mycobactria (NTM) infections by blocking the
autophagosomal clearance of human macrophages by pre-
venting lysosomal acidification, hence impairing autophagic
and phagosomal degradation. Hence macrolide therapy
may predispose NTM infections by hampering intracellular
mycobacterial killing in macrophages.
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Antibiotics delivered directly to the airways by nebulisation
have been shown to be very effective in managing pulmo-
nary complications of cystic fibrosis (CF).24 The benefits of
inhaled antibiotics are related to the local delivery of the
drug to the lung resulting in much higher sputum concen-
trations compared with that of intravenous or oral agents.
In addition, nebulised antibiotics seem to have a lower side
effect profile and toxicity. In the context of inhaled anti-
biotics therapies, it is important to highlight, the role of the
inhalation devices as they determine optimal particle size
and the lung deposition of the medication.25,26 Besides the
anti-microbial features of antibiotics, their bioavailability
as well as the profile of the adverse effects should also be
taken into account. A potential problem associated with
the long-term use of nebulised antibiotics is related to
patients’ adequate adherence with their medications.27
Despite some limitations, inhaled antibiotics have been
shown to be beneficial in CF patients, especially those with
chronic colonisation with P. aeruginosa.
Asthma
There is a reasonable body of evidence indicating attenu-
ation of corticosteroid requirements with the use of mac-
rolides in stable corticosteroid-dependent asthma patients.
It has been proposed that the anti-inflammatory mechanism
of macrolides is due to the inhibition of the cytochrome
P450 system (CYP3A4).28 Erythromycin, clarithromycin and
troleandomycin have been reported to reduce methyl-
predinsolone clearance in asthmatics29e32 besides inde-
pendently manifesting anti-inflammatory activity to those
of corticosteroids and theophyllines. Roxithromycin and
azithromycin do not inhibit the cytochrome P450 system,
but still are effective in reducing bronchial hyper-
responsiveness (BHR).33,34 Moreover macrolides by inhibit-
ing IL-6 and IL-8 may possibly lead to improvements in FEV1
in asthmatics.35,36 Several case series’ and open-labelled
studies using macrolides have been conducted in asth-
matic patients with positive outcomes.6,29,30,32e34,37e39 In
2005, a Cochrane review assessed the use of macrolides in
asthma.6 Seven studies with a total of 416 asthma patients
were considered based on an inclusion criteria of (sum-
marised in Table 1): the studies being double-blind placebo-
controlled (DBPC); 4 weeks of treatment in patients with
varying severity of asthma (clarithromycin e 3 studies,
roxithromycin e 2 studies; troleandomycin e 2 studies);
evaluation of asthma symptoms and at least one measure of
lung function (FEV1, FVC and/or PEF).
40e46 There were no
significant differences in forced expiratory volume in 1 s
(FEV1), and difference between forced vital capacity (FVC)
and corticosteroid usage in the studies. However, signifi-
cant improvements in favour of macrolides in symptom
control, BHR, attenuation in eosinophilic inflammation and
good drug tolerability. Despite the positive outcomes,
caution in the interpretation is vital as the studies include
small numbers, different macrolides assessed, a variety in
severities of asthma and chronic infection with Chlamydia
(C.) pneumonia, as well as diverse range outcome
measures.Following this review, a number of new studies have
been published in the literature using clarithromycin and
azithromycin. A trial on patients with severe refractory
asthma47 reported significant improvements in the
clarithromycin-treated group compared to placebo in Ju-
niper’s Asthma-related Quality of Life Questionnaire
(AQLQ) scores,48 and reduction in sputum IL-8 and neutro-
phils, and self-reported wheezing; particularly in the sub-
group of patients with non-eosinophilic (sputum) asthma
but there was no improvements in FEV1, hypertonic saline
challenge or sputum eosinophil counts. Piacentini et al.
conducted an 8 week trial on the efficacy of azithromycin
versus placebo on lung function, BHR and airway inflam-
mation in 16 asthmatic children49 and reported significant
reduction in hypertonic saline-induced BHR and sputum
neutrophilia in favour of the azithromycin-treated children
compared to placebo, but no changes in FEV1 between both
groups. In another randomised placebo-controlled, blinded,
allocation-concealed parallel group clinical trial in 45
adults with stable, persistent asthma, it was observed that
there were significant improvements in azithromycin-
treated (compared to placebo) subjects in asthma symp-
toms and rescue inhaler use during treatment that per-
sisted at 3 months after treatment, but not in the AQLQ.50
Of note, in the azithromycin-treated subjects the overall
asthma symptom improvement was higher in the subgroup
of patients with high immunoglobin (Ig) A to Chlamydia
pnuemoniae than in the lower IgA (28% vs. 12%), but not
significant. Moreover, there was a positive and significant
association between anti-Chlamydial IgA, but not anti-
Chlamydial IgG, with asthma symptom changes at 6
months. Hence, it was proposed that the anti-Chlamydial
IgA could help with 6-month asthma prognosis, as
measured by an overall asthma symptom scale. From the
various studies, we can see that there may be a possible
role for macrolides in chronic asthma; however their
routine use is not clearly justified based on current
evidence.Chronic Obstructive Pulmonary Disease (COPD)
Exacerbations of Chronic Obstructive Pulmonary Disease
(COPD) impair health status, accelerate the progression of
the disease and are associated with significant early mor-
tality.51 The frequency and severity of exacerbations is
associated with long-term mortality independent of co-
morbidities, FEV1, age and body mass index (BMI).
52
Airway inflammation plays a key role in the pathogenesis
of COPD and a variety of microbial organisms promote the
inflammatory process precipitating an acute exacerbation.
Given the role of inflammation and infections in COPD the
use of long-term antibiotics may offer a distinctive benefit
to control this disease.53
One of the earliest studies by Gomez and colleagues
observed a statistically significant reduction in the number
of acute infectious episodes and hospital admissions in
azithromycin-treated versus placebo following a 3-day
prophylactic treatment course every 21 days during the
winter months.54 The important trials are summarised in
Table 2.55e60 The first prospective study investigating the
efficacy of long-term macrolide therapy in patients with
Table 1 Summary of the studies of macrolides in asthma (Modified from Richeldi et al.6).
Study (Reference) Study design Number of subjects Duration of study Antibiotic Outcomes
Amayasu et al.40 Randomised DBPC
Crossover study
17 adult subjects with
mild-to-moderate atopic asthma
8 weeks CRM - Improvement in patients’ symptoms and
Methacholine PC20 in favour of CRM -No
change in FEV1 and FVC between Gps
- Reduction in blood and sputum eosinophil
counts, and sputum ECP
- No serious adverse events
Black et al.41 Randomised DBPC 219 asthmatic subjects with
serological evidence of
C. pneumoniae infection as
demonstrated by IgG and IgA
antibody titres
6 weeks RXM - Improvements in morning and evening
PEF in favour of RXM
- No significant changes symptom scores,
AQLQ or Chlamydia antibody titres
between Gps
- No serious adverse events
Kamada et al.42 Randomised DBPC
Gp A: TDM þ MP;
Gp B: TDM þ prednisolone;
Gp C: placebo þ MP
19 children (6e17 yrs) with
OCS-dependent asthma
(OCS tapering study)
12 weeks TDM - Improvements in all Gps in OCS reduction
compared to baseline (and between
Gp A and Gp C)
- Significant improvement in Gp A in
symptom scores
- Non-significant reduction in pulmonary
function in all Gps (except for
significant attenuation in FEV1 and
FEF25-75 in Gp B)
- Significant reduction in Methacholine
PC20 in Gp A
- No serious adverse events
Kostadima et al.43 Randomised DBPC of
Gp A: CRM b.i.d.;
Gp B: CRM t.i.d.;
Gp C: placebo
75 adult subjects with mild
persistent asthma
8 weeks CRM - Significant improvement in FEV1 in Gp B
- Significant improvement in Methacholine
PD20 in Gps A and B
- No changes in cortisol levels (in the
40 subjects that were assessed compared
to baseline)
Kraft et al.44 Randomised DBPC 55 adult subjects with moderate
persistent asthma (31 with
evidence of C. pneumoniae or
M. pneumoniae infection)
6 weeks CRM - No change in FEV1 between Gps
- No significant difference in IL-2, IL-4,
IL-5, IL-12 and TNF-a airway biopsies
and BAL between PCR þ ve and PCR eve
subjects
Subgroup analysis of PCR þ ve and eve
for C. pneumomiae or M. Pneumoniae
receiving CRM or placebo:
- Significant increase in FEV1 in PCR þ ve
subjects receiving CRM (not in PCR eve
or PCR þ ve subjects receiving placebo)
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- Significant reduction in IL-5, IL-12 and
TNF-a in BAL in PCR þ ve receiving CRM
and only the latter 2 mediators in PCR eve
receiving CRM
Significant reduction in TNF-a in airway
biopsies in PCR þ ve and eve receiving CRM
Nelson et al.45 Randomised DBPC of
TDM þ MP
vs. placebo þ MP
75 adult asthmatic subjects
with severe persistent asthma
(OCS tapering study)
52 weeks (single
blind for 52 weeks
for 57 subjects
[TDM n Z 30;
Placebo n Z 27]
TDM - Significant reduction in hospitalisation,
OCS for exacerbations, OCS tapering and
dual- photon densitometry of lumbar spine
in both Gps at 52 and 104 weeks compared
to baseline (but not between Gps)
- Significant increase in blood eosinophil
count and 60 min stimulated cortisol levels
at 52 weeks in both Gps
- Significant reduction in mean IgG level in
the TDM compared to placebo at 52 weeks
- Significant increase in mean fasting blood
sugar (at 104 weeks) and cholesterol levels
(at 52 and 104 weeks) in the TDM Gp than
placebo
- No significant improvement in Methacholine
PC20 between Gps
Shoji et al.46 Randomised DBPC
Crossover study
14 adult subjects with
aspirin-intolerant mild/moderate
asthma
8 weeks RXM - Significant reduction in symptom score
with RXM compared to placebo
- No significant differences between both in
pulmonary function, sulpyrine PC20 and
leukotriene E4 urinary elimination.
- Significant reduction with RXM in mean ECP
and eosinophil count in serum and sputum
compared to placebo
- No serious adverse events
Abbreviations: DBPC e Double-blind, placebo-controlled study; CRM e Clarithromycin; PC20 e Provocation concentration causing a % reduction in FEV1; Gp e Group; FEV1 e Forced
expiratory volume in 1 s; FVC e Forced vital capacity; ECP e Eosinophilic cationic protein; RXM e Roxithromycin; C. pneumomiae e C lamydia pneumoniae; Ig e Immunoglobulin; flow;
PEF e Peak expiratory flow; AQLQ e Asthma-related quality of life; TDM e Troleandomycin; MP e Methylprednisolone; yrs e yea ; OCS e Oral corticosteroids; FEF25e75 e Forced
expiratory flow 25%e75%; b.i.d e Twice daily; t.i.d. e thrice daily; PD20 e Provocation dose causing a 20% reduction in FEV1; M. pneum niae e Mycoplasma pneumoniae; IL e Interleukin;
TNF-a e Tumour necrosis factor alpha; PCR e Polymerase chain reaction; þve e Positive; eve e Negative; vs. e versus.
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Table 2 Summary of the studies of long term antibiotics in COPD.
Study Study design Number of
subjects
Duration of
study
Antibiotic Outcomes
Albert et al.55 Randomised
placebo
control study
1577 12 months Azithromycin250
mg daily
- Median time for first exacerbation
better for azithromycin group
- Reduced frequency of acute
exacerbations
- Reduced risk of acute exacerbations
- Improved quality of life
- Caused hearing decrements in a
small percentage
He et al.58 Randomised
DPBC trial
36 6 months Erythromycin125
mg three times daily
- lower mean exacerbation rate
- Delayed time for first exacerbation
favouring erythromycin
- Decreased sputum neutrophils
and neutrophil elastase
Blasi et al.57 Randomised
uncontrolled
trial
22 6 months Azithromycin 500
mg three times a week
- Lower cumulative number of
exacerbations and
hospitalisations-Reduction in the
time for first exacerbation-Improved
quality of life
Seemungal et al.59 Randomised
DPBC trial
109 12 months Erythromycin250
mg twice daily
- Reduced rate of exacerbations
- Shorter duration of exacerbations
- No difference in terms of stable FEV1,
serum CRP, sputum IL-6 or IL-8
Banerjee et al.56 Prospective
Randomised
DPBC trial
67 3 months Clarithromycin 500
mg once daily
- No change in health status,
exacerbation rate or sputum bacterial
numbers
Sethi et al.60 Randomised
DPBC trial
1157 48 months 6 courses of Moxifloxacin
400 mg OD for 5 days
- Reduction in the exacerbation rates
- No unexpected adverse events
Role of long term antibiotics in respiratory diseases 805stable COPD was an open-label, randomized trial of eryth-
romycin (200e400 mg/d) for 12 months in 109 patients with
COPD. Thirty patients (56%) compared to six patients (11%)
in the control group and erythromycin group respectively
had one or more exacerbations. Although this trial was
noteworthy, it was unblinded. However, not all the initial
trials were supportive of a role for long-term antibiotics.
Banerjee et al. examined the role of 3-months oral clari-
thromycin or placebo once-daily in 67 patients with
moderate-to-severe COPD. The authors concluded that
treatment of stable COPD with clarithromycin yielded no
clinical advantage and did not improve health status,
sputum bacterial numbers, or prevent infective exacerba-
tions.56 However, the short duration (3 months) of the
antibiotic could have had a bearing on the results. See-
mungal and colleagues in a randomized, DPBC study of 109
patients administered erythromycin 250 mg twice daily to
patients with moderate COPD (80% of patients on inhaled
corticosteroids) over 12 months.59 They found that eryth-
romycin treatment was associated with a significant
reduction in exacerbations compared with placebo, but had
no significant impact on FEV1, sputum inflammatory
markers, serum inflammatory markers or bacterial flora.
The frequency of side effects was low in both arms with no
differences between the two arms.
The results of the above studies suggest that macrolide
therapymay be beneficial in COPD patients preventing acuteexacerbations of COPD (AECOPD) and altering the natural
course of the disease. Whether this is due to its anti-
microbial properties or due to immunomodulation needs to
be established. The balance between inflammation and
immunomodulation is important in chronic airway diseases
and macrolides may have a possible effect on this balance in
addition to its anti-microbial effects to reduce AECOPD. That
said, a randomised DBPC trial in stable COPD patients with
pulsed moxifloxacin (moxifloxacin 400 mg/day) (NZ 573) or
placebo (N Z 584) once daily for 5 days and treatment
repeated every 8 weeks for a total of 6 courses found that at
48 weeks the odds ratio (OR) for suffering an exacerbation
was reduced by 20% in the intention-to-treat group.60 No
changes in the overall health status, rates of hospitalization
or mortality, or attenuation of lung function decline were
noted. Subgroup analyses demonstrated that the reduction
in exacerbations with moxifloxacin was seen in COPD of all
severity categories, supporting a role for quinolones in pre-
venting exacerbations.
Recently, Albert and colleagues conducted a multicenter
randomised trial of 1142 patients at risk of AECOPD to
receive 250 mg daily of azithromycin (n Z 570) or placebo
(nZ 572) for a year in addition to usual care.55 The primary
outcome i.e. time to first exacerbation was significantly
increased in the azithromycin group when compared to
placebo (226 days vs. 174 days). The hazard ratio for having
an acute exacerbation per patient year was 0.74 in the
806 K. Suresh Babu et al.azithromycin group. Although there was no significant
reduction in the hospitalisation rates, urgent care visits or
mortality between the two groups, azithromycin treatment
improved the QoL measures and had similar frequency of
serious adverse events in both groups except for hearing
loss and colonisation with macrolide-resistant organisms.
While there was a question on the role of long-term anti-
biotics in stable COPD to prevent exacerbations, the trial by
Albert et al. has provided support for the long-term use of
azithromycin to reduce exacerbations. It is still unclear
whether this beneficial effect is due to the anti-bacterial
properties or to the immunomodulatory effects of macro-
lides. Furthermore, the likely development of resistance to
antibiotics in the long-run and the role for azithromycin on
a once, twice or thrice weekly regimen, given the
extremely long tissue persistence of the drug needs to be
explored. Therefore, adverse effects of macrolides such as
hearing loss, effects on QTc and interactions with other
agents need to be taken into account and balanced against
possible benefits in individual patients. In addition, pa-
tients need ongoing assessments for potential benefits of
long term therapy with macrolides and at the same time be
aware of potential adverse effects. Although, there have
been no studies or guidelines recommended how long one
should administer macrolides to assess the efficacy of
macrolides, we suggest a trial of 3e6 months in the first
instance, followed by regular reviews on benefit vs adverse
events.Cystic fibrosis (CF)
CF is one of the most common genetic disorders61e63 in
which the main defect relates to the malfunction in the CF
trans-membrane conductance regulator (CFTR). This defect
in turn results in chronic respiratory infections which
remain the main cause of morbidity and mortality in
CF.64e67 In early CF, Staphylococcus (S.) aureus and Hae-
mophilus (H.) influenzae remain the main pathogens.24,61
However, overall the most commonly isolated pathogen in
CF is P aeruginosa. Recently, pathogens such as Bur-
kholderia (B.) cepacia and Stenotrophomonas (S.) malto-
philia have been reported in CF with increasing
frequency.24,61
Antibiotics in CF are used to manage exacerbations as
well as to prevent, eradicate and control respiratory in-
fections, hence potentially improving survival.24 Fluclox-
acillin, which has shown to reduce the incidence of
infection with S. aureus, has acquired long term use in
young children with CF aged up to 3 years.68 Similarly, other
oral agents in particular macrolides have been shown to be
beneficial in CF (Table 3).69e77 A number of studies have
shown that the long-term use of azithromycin in CF patients
resulted in improved lung function, reduction in a number
of infective exacerbations and the use of antibiotics.69e79
For example, Wolter et al. reported that in adults with
CF, azithromycin improved QoL, reduced both the number
of respiratory exacerbations, and the rate of decline in the
lung function.70 Similar outcomes were reported by Saiman
and colleagues with oral azithromycin in CF patients
chronically infected with P. aeruginosa.71 Although the
exact mode of action of macrolides in CF is not fullyunderstood, the benefits are mainly observed in patients
colonised with P. aeruginosa. However, some also reported
the benefit of long-term macrolides in CF patients even
prior to P. aeruginosa infection.73 Chronic colonisation with
P. aeruginosa is one of the main predictors of morbidity and
mortality in CF,80 hence the need to control this infection.
Numerous antibiotics have been tested for aerosolized
use in CF, including tobramycin, colomycin, gentamicin,
aztreonam and taurolidine and some of them have acquired
clinical use in CF.81e88 Nebulised antibiotics in CF have been
used to manage acute respiratory exacerbations as well as
chronic therapy to stabilise lung function and prevent
chronic colonisation with P. aeruginosa. For example,
studies have shown that treatment with nebulised colo-
mycin can lead to effective eradication of colonisation of P.
aeruginosa.81,82 In fact, three months thrice daily regime of
nebulised colistin showed that after 3.5 years only 16% of
treated patients had developed chronic P. aeruginosa
infection compared to 72% of untreated historical con-
trols.81 Similarly, studies revealed that in CF patients
inhaled tobramycin resulted in effective eradication of
early infection with P. aeruginosa.89 Moreover, long-term
intermittent administration of inhaled tobramycin has
been well tolerated and resulted in improved lung function
and decreased density of P. aeruginosa in the sputum as
well as reducing the risk of hospitalization.84,90 Similar
observations have been reported with nebulised tobramy-
cin and colomycin in CF patients colonised with P. aerugi-
nosa by others83; hence both of these agents are being
regularly used in clinical practice. A recent Cochrane re-
view on long term inhaled antibiotics in CF has concluded
that inhaled antibiotic treatment probably improves lung
function and reduces exacerbation rate, but a pooled es-
timate of the level of benefit was not possible. The best
evidence was for inhaled tobramycin.91
Amongst the new inhalation antibiotics approved for the
use in CF patients with P. aeruginosa colonisation is a
monobactam formulation, aztreonam lysinate.87,92 The use
of inhaled aztreonam in CF patients with P. aeruginosa
colonisation resulted in reduction of bacterial burden,
preservation of lung function, and improvement in symp-
toms associated with disease.93e95 McCoy and colleagues
observed that 28-days of nebulised aztreonam compared
with the placebo in CF patients on nebulised tobramycin
improved lung function, respiratory symptoms and reduced
sputum density of P. aeruginosa.93 Similar observations
were noted in an 18-month study with nebulised aztreonam
besides being well tolerated.95 Another novel inhaled
antibiotic tested in CF patients with chronic P. aeruginosa
includes an aerosol formulation of levofloxacin (MP-376,
Aeroquin).96 This new preparation of inhaled levofloxacin
resulted in improved lung function and reduction in anti-
biotics use. Geller et al. observed that in CF patients
colonised with P. aeruginosa nebulised levofloxacin was
well tolerated, improved FEV1 by 8.7% and reduced sputum
P. aeruginosa density.96
There have also been attempts to use nebulised antibi-
otics to treat CF patients colonised with B. cepacia as those
patients have an increased morbidity and mortality. Taur-
olidine is an antibiotic with a broad spectrum of activity
against gram negative and positive bacteria as well as being
an anti-endotoxin. Ledson and colleagues assessed the
Table 3 Summary of the studies of long term antibiotics in cystic fibrosis.
Study Study design Number of subjects Duration
of study
Antibiotic used Outcomes
Saiman et al.71 Randomised Placebo
controlled
185(87 treatment group) 6 months Azithromycin Improved FEV1, reduced number
of exacerbations,
Wolter et al.70 Randomised placebo
controlled
60 adult CF patients 3 months Azithromycin No decline in FEV1, fewer courses
of IV antibiotics, decline in C reactive
protein, improvement in QOL
Kabra et al.78 Randomised controlled 56 children 12 months Azithromycin low dose
5 mg/kg/day compared
with high dose
15 mg/kg/day
No difference in clinical score, FEV1
and pulmonary exacerbation rates
between the two groups
Hodson et al.83 Randomised controlled 115 4 weeks Nebulised colomycin
compared with nebulised
tobramycin
Both treatments reduced bacterial
load. Nebulised tobramycin improved
lung function in CF patients chronically
colonised with P. aeruginosa
Ramsey et al.84 Randomised placebo
controlled
520 24 weeks Nebulised tobramycin Improvement in pulmonary function,
decrease in the density of P. aeruginosa
in sputum, decreased risk of
hospitalization
McCoy et al.93 Randomised controlled 211 28 days Inhaled aztreonam
solution
Improvement in pulmonary function
and respiratory symptoms
Retsch-Bogart et al.94 Randomised placebo
controlled
164 28 days Inhaled aztreonam
solution
Improvement in pulmonary function
and respiratory symptoms
Oermann et al.95 Open label 274 18 moths Inhaled aztreonam
solution
Clinical benefits in pulmonary function,
health-related quality of life, and weight
Ledson et al.88 Randomised double
blinded cross over
20 4 weeks Inhaled taurolidine No change in B. cepacia colony count or
spirometry, nor symptom score
Frederiksen et al.81 Comparison with
historical control
48 patients compared
with 43 control
44 moths Inhalation of colistin
and oral ciprofloxacin
16% of the treated patients developed
chronic P. aeruginosa infection compared
with 72% of the control patients (P < 0.005),
improvement in lung function
Gibson et al.89 Randomised double
blind
21 28 days Inhaled tobramycin Reduction in P. aeruginosa density
Geller et al.96 Randomised placebo
controlled
151 28 days Inhaled ciprofloxacin Reduction in P. aeruginosa density,
improvement in pulmonary function (FEV1),
reduction in need for anti-pseudomonal
antibiotics
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808 K. Suresh Babu et al.effects of inhaled taurolidine in CF patients infected with
B. cepacia.88 Although Taurolidine was well tolerated it did
not affect the B. cepacia colony count or other outcomes
assessed. Inhaled formulations of ciprofloxacin have shown
promise in patients with non-CF bronchiectasis97 and will be
of interest to see whether similar effects will be seen in CF.
Overall the use of inhaled antibiotics in CF has been widely
accepted. The main role of inhaled antibiotics in CF has
been in patients with chronic colonisation with P. aerugi-
nosa, however there are potential new agents currently
being assessed which may acquire clinical use in the future.Non-CF bronchiectasis
Long-term antibiotics in bronchiectasis reduces exacerba-
tions, improves symptoms and QoL by reducing bacterial
load and airway inflammation.98 The early evidence for
long-term antibiotics in bronchiectasis stems from the MRC
multi-centre study where 122 patients with bronchiectasis
were allocated to penicillin (n Z 38), oxytetracycline
(n Z 44) and placebo (n Z 40). After a year, in the
oxytetracycline group there was a 64% reduction in sputum
volume, had fewer days off work; fewer days confined to
bed and reduced episodes of fever. Unfortunately, no
formal statistical analyses were performed.99 Currie et al.
in a randomised placebo controlled trial evaluated the ef-
fect of high-dose amoxicillin (3 gm twice daily) in 38 pa-
tients with bronchiectasis.100 The frequency of
exacerbations during the study treatment phase was similar
in both groups, but they were less severe than before study
treatment in the amoxicillin group. There was a greater
reduction in purulent sputum volume between exacerba-
tions during the study treatment in the amoxicillin group
compared to placebo. Independent assessment of the
overall response based on patients’ diary cards showed that
a higher proportion improved in the amoxicillin-treated (11
of 17) compared to placebo (4 of 19). Adverse events
experienced by patients were minor and there was no
change in the bacterial flora based on sputum and stool
cultures. More recently a New Zealand group conducted a
DBPC study to evaluate the role of azithromycin in reducing
frequency of exacerbations, improvement in lung function
and health-related QoL in 141 (71 azithromycin; 70 pla-
cebo) patients with non-CF bronchiectasis for 6 months.101
They reported a significant reduction in the rate of exac-
erbations but no differences in the other parameters
assessed.
Studies in non-CF bronchiectasis include both oral and
nebulised antibiotics and are summarised in Table
4.100,102e106 Davies and colleagues in an open-labelled
prospective trial evaluated the role of azithromycin
250 mg thrice/wk for 4 months in 39 bronchiectasis pa-
tients.102 All the patients had more than 4 documented
exacerbations during the previous 12 months. There was a
reduction in exacerbations warranting oral and intravenous
antibiotics, and an improvement in TLCO. Yalcin and col-
leagues examined the effects of clarithromycin on inflam-
matory markers (IL-8, TNF-alpha, IL-10 levels and cell
profiles in bronchoalveolar lavage (BAL) fluid, pulmonary
function and sputum production in children with non-CF
bronchiectasis in a randomised DBPC trial.106 Following 3months of treatment compared to placebo, the
clarithromycin-treated subjects showed a significant
decrease in IL-8 levels, total cell count, neutrophil ratios in
BAL fluid and daily sputum production, but no significant
differences in pulmonary function test parameters. Barker
and colleagues examined the microbiological efficacy and
safety of nebulised tobramycin twice daily for 4 weeks in 74
patients with bronchiectasis and P. aeruginosa in a rando-
mised DBPC trial (nZ 37 in each group).107 At Week-4, the
treatment group had a mean decrease in P. aeruginosa
density of 4.54 log10 colony-forming units/g sputum
(p < 0.01). At Week-6, P. aeruginosawas eradicated in 35%
in the treatment group but was detected in all placebo
patients. No differences in lung function were reported.
This study supported a role for nebulised antibiotics in
bronchiectasis, albeit for a 4-week duration.
In a trial involving 30 bronchiectatic patients with neb-
ulised tobramycin for 6 months with103 there was a reduc-
tion in hospital admissions and in-patient days during
treatment phase and a decrease in P. aeruginosa density up
to 3 months of stopping tobramycin. However, there was no
difference in exacerbations, antibiotic use, lung function or
QoL between the treatment periods. Another trial involving
nebulised ceftazidime and tobramycin twice daily in pa-
tients with bronchiectasis concluded that the treatment
group had less admissions and in-patient days, but there
was no difference in the lung function or use of oral anti-
biotics use between groups.105 More recently, a study from
Edinburgh randomised sixty-five patients to either twice
daily nebulised gentamicin, or 0.9% saline, for 12
months.104 At 12 months the treatment group had reduced
sputum bacterial density with 30.8% eradication in those
infected with P. aeruginosa and 92.8% eradication in those
infected with other pathogens; less sputum purulence;
greater exercise capacity and fewer exacerbations with
increased time to first exacerbation. No differences were
seen in 24-h sputum volume and lung function parameters.
Of note, P. aeruginosa isolates developed resistance to
gentamicin. Recently, the ORBIT 1 study evaluated the ef-
ficacy, safety, and tolerability of once daily inhaled cipro-
floxacin in the management of P. aeruginosa infections in
patients with non-CF bronchiectasis.97 The data revealed
that at 28 days nebulised ciprofloxacin reduced P. aerugi-
nosa density and improved QoL. Murray et al. conducted a
1-year randomised placebo controlled study assessing the
efficacy of nebulised gentamicin compared to placebo in a
number of sputum, objective, subjective and exacerbations
parameters.104 They reported substantial improvements
sputum bacterial density with over 30% having eradicated P.
aeruginosa and over 90% eradicating other pathogens,
sputum purulence, fewer exacerbations and delay to first
exacerbations, improved exercise capacity as well as
improvement in subjective parameters of cough and QoL.
Moreover there were no P. aeroginosa isolates developing
resistance to gentamicin. Of note, there were no
improvement sin 24-h sputum volume and various assess-
ments of lung function.
There is consistent evidence that long-term antibiotics
either oral or nebulised improves QoL, decreases exacer-
bation frequency and reduces the bacterial load. Unlike the
CF experience, there does not seem to be an improvement
of pulmonary function after treatment with nebulised
Table 4 Summary of the studies of long term antibiotics in Non-CF bronchiectasis.
Study Study design Number of
subjects
Duration of study Antibiotic Outcomes
Murray et al.104 Randomised
placebo
controlled
trial
65 12 months Neb gentamicin
80 mg twice daily
- Reduction in bacterial load
- Decrease in number of
exacerbations
- Significant prolongation for
time to first exacerbation
- Bronchospasm observed in
21.9% (Vs 6% in placebo)
Orriols et al.105 Open labelled
study
17 12 months Neb ceftazidime
1 gm bd & Neb
tobramycin 100 mg
bd or placebo
- Reduced number of admissions
& in-patient stays
- No difference in the use of
oral antibiotics
- No changes in lung function
Drobnic et al.103 Double blind
placebo
controlled
crossover
trial
30 6 months Nebulised tobramycin
300 mg twice daily
- Reduction in the number of
admissions
- Reduction in hospital stays
- Reduction in pseudomonas
density in sputum
- No difference in number of
exacerbations or QOL
Yalcin et al.106 Randomised
placebo
controlled
34 (children) 3 months Clarithromycin
15 mg/kg
- Reduction in sputum volume
- Improvement in maximal
mid-expiratory flow
- No change in FEV1
Davies et al.102 Prospective
open
labelled
39 10 months Azithromycin 250 mg
three times weekly
- Decreased exacerbation
frequency
- Decreased need for IV
antibiotics
- Improvement in symptoms
and TLCO
Currie et al.100 Randomised
placebo
controlled
38 32 weeks Amoxicillin 39 twice
daily
- Similar frequency of
exacerbations but less
severe in the amoxicillin group
- Greater reduction in sputum
purulence
- Less time confined to bed and
away from work
Role of long term antibiotics in respiratory diseases 809antibiotics. In practice, the prescription of long-term an-
tibiotics should be considered for patients exacerbating at
least 3 times/yr and in patients with fewer exacerbations
but with greater morbidity.108 There may also be a lower
threshold for starting long-term antibiotics in patients with
primary or secondary immunodeficiency. Antibiotic choices
should be based on sputum microbiology and careful
monitoring needs to be in place regarding microbial resis-
tance and adverse events.Diffuse panbronchiolitis (DPB)
DPB is a chronic respiratory condition of unknown aetiology,
almost exclusively described in the Far East (mainly Japan,
but also Korea and China), characterised by chronic
inflammation of the respiratory tract with progressive
destruction of the lung parenchyma.109e111 Up to the early
1980s DPB was a fatal condition, however with the use oflong-term macrolides it is now a very treatable condition
with its 5-year prognosis increasing from 63% in the 1970s to
about 90% in the late 1990s.112 Initially, case reports and
series’ using low-dose erythromycin112,113 reported clinical
and radiological improvements in patients with DPB, but
recent reports have also reported similar positive findings
with clarithromycin, roxithromycin and azithromycin (Table
5).114e117 A recent Cochrane review reported that, of the
many studies assessed only one was identified to have
adequate quality.4 In this study of 19 subjects with DPB, 12
were randomly assigned to receive low-dose erythromycin
and rest no treatment.118 It was observed that compared to
the pre-treatment CT scan, there were marked improve-
ments in the interval CT scan in all subjects following
treatment with the erythromycin. Of note, 71.4% of the
control group subjects had worsening of their interval scan.
This study had a number of methodological errors with no
fixed times of treatments, interval scans, and mention of
adverse events besides the small cohort of subjects.
Table 5 Summary of the studies of macrolides in diffuse panbronchiolitis.
Study Study design Number of subjects Duration of study Antibiotic used Outcomes
Akira et al.118 Observational RCT of
efficacy of macrolide
treatment
19 subjects (12 active
treatment and 7 no
treatment)
Not specified Erythromycin - CT scans showed a reduction in number and size
of centrilobular and branched linear airways of
high attenuation in all subjects.
- No change to airway dilatation or peripheral
areas of lung attenuation. In the untreated
group progression of disease was noted in
71.4% of subjects.
Kudoh et al.112 Retrospective
observational survival
study based on year
of diagnosis
498 subjects(Gp
A: 1970e79 [only std
ABx avail} [n Z 190];
Gp B: 1980e84
[quinolones avail][n Z 221];
Gp C: 1985e90
(Erythromycin avail}
[n Z 87])
N/A Erythromycin - Survival rate of Gp C was significantly higher
than Gps A and B.
- Of the 87 in Gp C 5/24 died in patients not
receiving ERM compared to 3/63 from ERM treated.
- Efficacy of ERM increased survival in older
compared to younger subjects.
Yamamoto et al.134 Retrospective
observational study
comparing quinolone
vs. macrolide
101 subjects N/A Erythromycin Significant improvements in favour of ERM in:
- Exertional dyspnoea
- CXR findings, PaO2
- ESR, titre of cold agglutination
- Amount of sputum in favour of ERM
Kobayashi et al.117 Open-labelled study
of efficacy and safety
60 subjects (efficacy
data on 52 and safety
data on 55)
12 weeks Azithromycin - Efficacy rate was 86.6% (44/52)
- Sputum reduction 65.2% (30/46)
- Reduction in exertional dyspnoea 50% (23/46)
- Improvement in FEV1, cold agglutination and CRP
in smaller numbers of subjects.
- Eradication of sputum organisms 39.5% (15/38)
Kadota et al.115 Prospective
open-labelled study
10 subjects 4 years Clarithromycin - FEV1 and FVC improved within 6 months in most
subjects.
- PaO2 at rest improved in 3e6 months.
- Improvement in the comprehensive improvement
score in 6 months (in 9 subjects).
- Negative sputum cultures in majority of subjects
at 6 months.
- No adverse events with the use of CRM.
Abbreviations: RCT e Randomised control trial; CT scan e Computed tomography scan; Gp e Group; std e standard; ABx e antibiotics; avail e available; n e number; N/A e Not
applicable; vs. e versus; CXR e Chest X-ray; PaO2 e Partial pressure of oxygen in arterial blood; ESR e erythrocyte sedimentation rate; FEV1 e Forced expiratory volume in 1 s; CRP e
C-reactive protein; FVC e Forced vital capacity.
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Role of long term antibiotics in respiratory diseases 811Despite the lack of large RCTs to confirm the efficacy and
safety of macrolides in DPB, the Ministry of Health and
Welfare of Japan have implemented the use of macrolides
in its treatment on diagnosis for 6-months based on the
observational studies and expert opinion.Post-transplant bronchiolitis obliterans
syndrome (BOS)
Obliterative bronchiolitis (OB) is an airway inflammatory
process that results in significant long-term morbidity and
mortality in post-transplant patients, mainly of the lung,
but also of other organs, synonymous with chronic graft
rejection.119e121 Although OB is thought to be mainly
immunologically mediated and is rarely successfully
managed with the use of immunosuppressive agents, sig-
nificant numbers of transplant patients experience con-
current bacterial and non-bacterial infections which may
worsen lung inflammation and potentially worsen the
chronic rejection. Azithromycin has been examined in
several small post-lung transplant studies with potential
benefits, but this has been questioned. Four prospective
open-labelled studies with azithromycin treatment have
been described in the literature, 3 have shown significant
improvements in FEV1,
122e124 but 1 showing no improve-
ment in FEV1.
125 Furthermore, 2 retrospective case series’
using azithromycin have been conducted, one reporting
positive FEV1 improvements beyond 3 months of treatment
cessation in a majority of patients,126 but the other did
not.127 In the largest prospective study of 14 lung transplant
patients receiving azithromycin for 3 months, besides the
mean increase in FEV1, it was reported that BAL neutro-
phils, % neutrophils and IL-8 mRNA ratio decreased signifi-
cantly but had no impact on IL-17 mRNA ratio.124 They
noted a responder group of 6 patients (increase >10% FEV1)
who had a marked reduction in %BAL neutrophilia, IL-8
mRNA and IL-17 mRNA. Moreover, they reported a signifi-
cantly positive correlation between the initial %BAL neu-
trophilia and response to treatment. Of note, a BAL
neutrophilia of >15% had a positive predictive value of 85%
for a significant FEV1 response to azithromycin, and that a
BAL neutrophilia <15% had a negative predictive value of
100%.124 Similar positive and negative predictive values
have been reported by another group.128
The clinical benefits of azithromycin have been hypoth-
esised to be due to: the pro-kinetic effect diminishing
the gastro-oesophageal reflux122 and enzyme inhibition,
increasing the plasma concentrations of
immunosupressors.123e126 However, these have not been
substantiated. The role of C. pneumoniae infection has been
implicated in the development of BOS, with donor-recipient
serology mismatch (i.e. donor positive/recipient negative)
being an independent risk factor for BOS development.129
Furthermore, it has been reported that C. pneumoniae
infection in lung transplant patients is associated with poor
outcome and increased risk of BOS.130 From the available
data, azithromycin has been associated with positive out-
comes; physicians need to be cautious that this therapy is not
viewed as a panacea for treatment of BOS, and that larger
clinical trial with long-term follow-up are needed to deter-
mine the benefits in all and responding patients.Opinions and conclusions
Different macrolides have variable pharmacokinetic and
pharmcodynamic properties such as the long half-life of
azithromycin and its higher concentration in sputum,131,132
whereas roxithromycin with its higher anti-inflammatory
activity,133 compared to other macrolides. It is also not
clear as to whether the actual mechanism of action of
macrolides is due to the anti-microbial (deep-seated infec-
tion clearance), anti-reflux or anti-inflammatory, and in
certain cases anti-fibrotic properties. From this it appears
that macrolides may manifest their biological efficacy in a
range of respiratory conditions through a number of recog-
nised potential mechanisms or others that still yet to be
established. To investigate these mechanisms needs sub-
stantial effort and collaboration between clinicians and
scientists not only in translational studies, but also on the
bench. From the available evidence it should be noted that
guidelines recommend the use of macrolides in the man-
agement of CF (azithromycin in particular) and pan-
bronchiolitis. In the former, the recommendations are based
on well designed DBPC studies and meta-analyses and in the
latter by consensus opinion (Japanese health authority). In
the remaining conditions discussed in this review the data
are not so stringently clear and hence there remains a need
for well-conducted studies to establish their efficacy. Lastly,
it may be that with the aid of these mechanistic and
efficacy-based studies in the future, we may be in a better
position to determine a disease-specific macrolide, i.e.
‘tailored treatment’ for the individual patients.
Aerosolised antibiotics deliver anti-microbial therapy to
diseased lungs, hence providing targeted therapy with
possibly limited adverse events to patients. Most of the
current available data on inhaled antibiotics involve anti-
pseudomonal agents which if administered early enough
may help with eradication, or in the long-term reduce the
risk of recurrent infections especially in CF and non-CF
bronchiectasis patients.
In this review we have highlighted the various respira-
tory conditions in which long-term antibiotics, oral or
nebulised, have been investigated. The data is more robust
in CF (nebulised antibiotics and oral azithromycin)
compared to non-CF bronchiectasis, panbronchiolitis and
COPD, and even less so with asthma and BOOP. The CF
model can serve as a foundation to investigate the role of
long-term antibiotics, especially nebulised in non-CF
bronchiectasis. Identification of the precise mechanism of
anti-inflammatory effect of macrolides would encourage
development of newer molecules with immunomodulatory
effects, hence circumventing the anti-bacterial effects.
There appears to be a role for long-term antibiotics,
especially macrolides, in a number of chronic inflammatory
airway disorders, however there is an urgent need to
establish this by performing longer, macrolide-specific,
DBPC and bench studies to establish their efficacy, safety
and mechanisms of action.
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